Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$33.97

-0.055 (-0.16%)

12:37
05/19/17
05/19
12:37
05/19/17
12:37

AstraZeneca announces positive CHMP opinion for brodalumab

AstraZeneca announced that its partner LEO Pharma has received a positive opinion from the Committee for Medicinal Products for Human Us eof the European Medicines Agency recommending the approval of brodalumab for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Brodalumab is the first and only fully human monoclonal antibody that selectively targets the IL-17 receptor. By binding to the receptor, brodalumab effectively blocks the biological activity of several pro-inflammatory IL-17 cytokines, which are important in psoriasis, a chronic, debilitating skin disease that causes red patches of skin covered with silvery scales. In July 2016, AstraZeneca announced an agreement granting LEO Pharma exclusive rights to develop and commercialise brodalumab in Europe. The announcement follows the approval of brodalumab by the US Food and Drug Administration in February 2017 and the approval by the Japanese Pharmaceuticals and Medical Devices Agency in 2016. The CHMP's positive opinion on brodalumab will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union.The final decision is applicable to all EU and European Economic Area countries. Reference Link

  • 19

    May

  • 26

    Jun

AZN AstraZeneca
$33.97

-0.055 (-0.16%)

05/12/17
05/12/17
UPGRADE

Neutral
AstraZeneca upgraded to Neutral at Credit Suisse
As previously reported, Credit Suisse analyst Rebekah Harper upgraded AstraZeneca to Neutral from Underperform after the company reported surprise positive headline results from the Phase 3 PACIFIC trial for Imfinzi in stage 3 unresectable lung cancer in all-comers, with positive progression free survival data. The analyst believes that AstraZeneca is in a "unique position" with this indication, with a likely two to three years lead versus competitors, as other P3s are not due until 2020+. Harper expects U.S. approval for AstraZeneca in this indication before the end of 2017.
05/15/17
LEER
05/15/17
NO CHANGE
LEER
GlaxoSmithKline possible move to buyout Novartis stake makes sense, says Leerink
Leerink analyst Seamus Fernandez is not surprised by the news that GlaxoSmithKline (GSK) may buyout Novartis' (NVS) 36.5% stake in its Consumer Healthcare joint venture through a GBP8B deal sooner rather than later. The analyst believes this buyout could be beneficial as the infusion of additional cash from the buyout could bolster Novartis appetite for large scale M&A, including companies such as AstraZeneca (AZN) whose immune-oncology assets could complement its small-molecule focused oncology portfolio, according to the London Times.
05/16/17
LEER
05/16/17
NO CHANGE
Target $36
LEER
Outperform
AstraZeneca price target raised to $36 from $33 at Leerink
Leerink analyst Seamus Fernandez raised his price target for AstraZeneca to $36 after hosting a call with a lung cancer specialist. The specialist believes that once approved, the uptake of AstraZeneca's Imfinzi in Stage III unresectable non-small cell lung cancer will be "significant" given the poor outcomes and general lack of an effective treatment standard in this setting, Fernandez tells investors in a research note. The analyst raised his peak worldwide forecasts for the drug by $1B and keeps an Outperform rating on AstraZeneca.
05/17/17
JPMS
05/17/17
UPGRADE
Target $72
JPMS
Overweight
Clovis upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Cory Kasimov upgraded Clovis Oncology (CLVS) to Overweight and raised his price target for the shares to $72 from $58. The stock closed yesterday up 2%, or $1.05, to $49.56. The shares are down 35% over the last two months for "no clear fundamental reason," Kasimov tells investors in a research note. The analyst is "increasingly comfortable" recommending Clovis ahead of its Phase 3 study evaluating Rubraca in maintenance ovarian cancer now that more PARP class data has emerged. He has not seen "convincing evidence" that there is a clear efficacy difference between Clovis' rucaparib, Tesaro's (TSRO) niraparib and AstraZeneca's (AZN) olaparib.

TODAY'S FREE FLY STORIES

HON

Honeywell

$131.70

-0.14 (-0.11%)

14:42
05/23/17
05/23
14:42
05/23/17
14:42
Hot Stocks
Breaking Hot Stocks news story on Honeywell »

Honeywell CEO says thinks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

X

U.S. Steel

$20.39

0.9169 (4.71%)

14:40
05/23/17
05/23
14:40
05/23/17
14:40
Options
US Steel calls outpace puts nearly 3:1 as shares rally »

US Steel calls outpace…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOMO

Momo

$42.83

-0.75 (-1.72%)

14:39
05/23/17
05/23
14:39
05/23/17
14:39
Downgrade
Momo rating change  »

Momo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

AZO

AutoZone

$596.00

-63.49 (-9.63%)

14:39
05/23/17
05/23
14:39
05/23/17
14:39
Recommendations
AutoZone analyst commentary  »

AutoZone weakness an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

HON

Honeywell

$131.63

-0.21 (-0.16%)

14:37
05/23/17
05/23
14:37
05/23/17
14:37
Hot Stocks
Breaking Hot Stocks news story on Honeywell »

Honeywell CEO says he…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

ALXN

Alexion

$115.42

1.58 (1.39%)

14:31
05/23/17
05/23
14:31
05/23/17
14:31
Recommendations
Alexion analyst commentary  »

Alexion should be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

RBS

RBS

$6.95

0.09 (1.31%)

14:30
05/23/17
05/23
14:30
05/23/17
14:30
Options
Royal Bank of Scotland sees put buying »

Royal Bank of Scotland…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

HON

Honeywell

$131.98

0.14 (0.11%)

14:29
05/23/17
05/23
14:29
05/23/17
14:29
Hot Stocks
Honeywell says spinoff of aerospace is 'intriguing concept' »

This comment was made…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

HON

Honeywell

$132.08

0.235 (0.18%)

14:25
05/23/17
05/23
14:25
05/23/17
14:25
Hot Stocks
Honeywell to shape portfolio changes over next 2-3 years »

Comments are from EPG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

HLF

Herbalife

$69.44

-4 (-5.45%)

14:21
05/23/17
05/23
14:21
05/23/17
14:21
Technical Analysis
Technical Analysis: Herbalife falls on report China executive departs »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BG

Bunge

$80.28

10.21 (14.57%)

14:20
05/23/17
05/23
14:20
05/23/17
14:20
Options
Newsbots go Bungee jumping this afternoon »

Newsbots go Bungee…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$122.18

0.52 (0.43%)

14:18
05/23/17
05/23
14:18
05/23/17
14:18
Hot Stocks
United Technologies CEO not interested in split »

Speaking at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

MOMO

Momo

$42.83

-0.75 (-1.72%)

14:17
05/23/17
05/23
14:17
05/23/17
14:17
Recommendations
Momo analyst commentary  »

Momo price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

$NSD

NASDAQ Market Internals

14:17
05/23/17
05/23
14:17
05/23/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
05/23/17
05/23
14:16
05/23/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIG

AIG

$61.56

0.175 (0.29%)

14:12
05/23/17
05/23
14:12
05/23/17
14:12
Hot Stocks
A.M. Best affirms AIG credit ratings, removes from under review »

A.M. Best has removed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

BWLD

Buffalo Wild Wings

$150.60

-2 (-1.31%)

14:11
05/23/17
05/23
14:11
05/23/17
14:11
Technical Analysis
Technical Analysis: Buffalo Wild Wings trades at session lows »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HON

Honeywell

$131.96

0.12 (0.09%)

14:11
05/23/17
05/23
14:11
05/23/17
14:11
Earnings
Honeywell backs FY17 EPS view $6.90-$7.10, consensus $7.09 »

Backs FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

HON

Honeywell

$131.98

0.14 (0.11%)

14:08
05/23/17
05/23
14:08
05/23/17
14:08
Earnings
Honeywell backs Q2 EPS view $1.75-$1.80, consensus $1.78 »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

WRB

W. R. Berkley

$67.93

0.26 (0.38%)

14:05
05/23/17
05/23
14:05
05/23/17
14:05
Hot Stocks
Ca. Insurance Commissioner announces $12M settlement with W. R. Berkley »

California Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNB

F.N.B.

$13.70

0.205 (1.52%)

14:05
05/23/17
05/23
14:05
05/23/17
14:05
Hot Stocks
F.N.B. implements board succession plan, says CEO to become chairman »

F.N.B. Corp announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRG

NRG Energy

$16.10

0.14 (0.88%)

14:02
05/23/17
05/23
14:02
05/23/17
14:02
Hot Stocks
NRG Energy looks to reorganize GenOn debt »

Earlier today,NRG Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$83.11

-0.94 (-1.12%)

14:00
05/23/17
05/23
14:00
05/23/17
14:00
Options
Bullish pre-earnings option play opened in Lowe's »

Bullish pre-earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

BWLD

Buffalo Wild Wings

$150.60

-2 (-1.31%)

13:59
05/23/17
05/23
13:59
05/23/17
13:59
Hot Stocks
Buffalo Wild Wings issues presentation on Marcato's 'misleading statements' »

Buffalo Wild Wings, in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCO

Taubman Centers

$60.90

0.55 (0.91%)

13:58
05/23/17
05/23
13:58
05/23/17
13:58
Hot Stocks
Taubman believes ISS, Glass Lewis 'erred' in their director recommendations »

Taubman Centers issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.